Highly Potent Drugs

May 31st 2023

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.

March 3rd 2023

The new guidance provides detailed recommendations to drug developers with a target of helping to ensure that drug developers provide adequate information to assess potency at each stage of a product’s life cycle.

January 28th 2022

Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.

December 1st 2021

CordenPharma will build a clinical trial development facility for manufacture of oral solid dosage drug products at its Plankstadt facility near Heidelberg, Germany.